OptiBiotix Health Reports Strong 2025 Results with Record Orders and Strategic Shift to Profitability

OptiBiotix has put out a much better set of numbers on the sales line, and the headline message is clear enough: growth is finally showing up in a more meaningful way, margins are improving, and management is now switching from building the platform to trying to make each part of the business pay its way.

That matters because this has been the big investor question for years. The science and product portfolio have never really been the whole issue – commercial delivery has been. On that front, 2025 looks like a step forward, while early 2026 looks stronger again.

OptiBiotix 2025 results explained – the key numbers retail investors should focus on

Metric	2025	2024
Revenue	£1.17 million	£870k
Gross profit	£614k	£331k
Gross profit margin	53%	38%
Operating loss	£3.13 million	£2.27 million
Total comprehensive loss	£3.89 million	£1.81 million
Cash	£1.04 million	£739k
Gross assets	£6.9 million	£9.0 million
PBX and SBTX holdings value	£6.45 million	£9.23 million

The good bit is obvious. Revenue rose 34% to £1.17 million, and gross profit jumped 85% to £614k. Even better, the gross profit margin – basically how much is left after direct production costs – improved sharply to 53% from 38%.

That kind of margin move is important. It suggests the business is not just selling more, but selling more efficiently. For a small growth company, that is exactly what you want to see before any serious push towards break-even.

Why OptiBiotix gross margin improvement is more important than the headline revenue rise

Lots of small caps can grow revenue for a while without creating much value. What makes this RNS more interesting is that gross margin moved up by 15 percentage points, which fed through into a much stronger gross profit performance.

There is also another useful detail tucked into the announcement: £212k of orders received in 2025 were not booked as revenue and were carried forward into 2026 for delivery. In simple terms, that means some commercial momentum was already there but had not yet shown up in the 2025 revenue figure.

Management says SlimBiome production costs should reduce by 31% in Q2 2026 orders, with further changes potentially taking that reduction to 48%. If that happens as planned, then margins could improve again from here. That is a big deal, because higher-margin growth is what gives this story a route to sustainability.

Record 2026 orders give OptiBiotix a stronger runway into profitability

The standout post-period number is the record start to 2026. OptiBiotix says it received over £800k of orders in January 2026 alone for delivery during the 2026 calendar year, including those carried forward orders.

That excludes ecommerce and any later orders, so it is a decent early indicator rather than the full picture. On top of that, the company flagged a 24 metric tonne SlimBiome order from Meelung Trading in Taiwan, to be delivered at roughly three-month intervals through 2026, with payment already received for the first 12 metric tonnes.

For retail investors, this is the bit that changes the tone. A business can talk about potential all day long, but hard orders are far more persuasive. It gives investors something measurable to track through the year.

OptiBiotix strategic shift – less empire building, more commercial discipline

Management is now openly saying the build-out phase is largely complete. The new emphasis is on high-growth areas, tighter spending and making each unit stand on its own two feet.

• Marketing and selling costs in January and February 2026 were reduced by 78%
• Planned R&D and IP cost reductions are expected to save £500k-600k per year
• Each business unit is being tasked with covering its direct costs by the end of 2026

That is the right shift in my view. Investors have heard for a long time about patents, studies, territories and opportunities. What they need now is evidence that these assets can produce repeatable profits, not just interesting presentations.

There is also a notable improvement in internal reporting, with separate profit and loss accounts for OptiBiotix Health USA, OptiBiotix Health India, Ecommerce and B2B. That sounds boring, but it matters. Better divisional accountability usually leads to better capital allocation.

SlimBiome, SweetBiotix and WellBiome – where the commercial upside sits

SlimBiome remains the lead commercial asset. The launch in Hydroxycut is a useful credibility marker because Hydroxycut markets itself as the number one selling weight loss supplement brand in the USA. The company also highlighted launches with Daily Nouri and Natural Health Trends Corporation.

Asia looks particularly encouraging. Revenue from territories outside the UK reached 73% of total revenue, and Asia increased by 182% to £268k from £95k. OptiBiotix says it now has 74 customer projects in development and 17 products launched across six countries.

SweetBiotix is still more of a future-value story, but there has been genuine progress. The new enzyme-based production process is said to deliver higher yields, a purer and better-tasting product, and lower production costs. If true at scale, that improves the odds of turning SweetBiotix from an interesting science project into a commercially useful ingredient platform.

WellBiome is not moving the revenue dial yet, but the Hull University Teaching Hospital study is worth watching. An NHS-led, double-blind, placebo-controlled trial looking at time in intensive care and potential cost savings is the sort of validation that could be very powerful if results are positive.

What is still not great in these OptiBiotix final results

Now for the reality check. The business is still loss-making, and the statutory loss got worse. Total comprehensive loss widened to £3.89 million from £1.81 million, while operating loss increased to £3.13 million from £2.27 million.

Some of that was inflated by £1.06 million of share-based payments, which is a non-cash accounting charge linked to options and warrants rather than cash leaving the bank. Even so, this is not a profitable company yet, and investors should not pretend otherwise.

The balance sheet also became less robust on paper. Gross assets fell to £6.9 million from £9.0 million, and the value of its PBX and SBTX holdings fell to £6.45 million from £9.23 million at year-end.

There is a further complication with SBTX. OptiBiotix disclosed that SBTX shares were suspended from trading on AIM on 31 March 2026, and OptiBiotix sold 8,900,000 SBTX shares in March and April 2026 for approximately £787k in cash. The cash helps, but the backdrop is hardly ideal.

The company also admits it remains dependent on a small number of key accounts in India and the USA. That concentration risk is real. One lost partner can hurt a small business much more than investors expect.

OptiBiotix investor verdict – better momentum, but 2026 execution is everything

My read is that this is a good RNS, but not a victory lap. The positives are real: revenue growth, much better gross margins, more cash, no debt, record orders into 2026 and a clearer cost-cutting plan.

The negatives are real too: large losses, reliance on a few accounts, and investment asset values moving the wrong way. So the share case now comes down to execution. If management can turn those January orders into delivered revenue, hold margins above 2025 levels and make the cost savings stick, then the path to commercial sustainability starts to look credible.

If not, investors will be left with another year of promise without enough profit. That is why 2026 matters more than 2025. The groundwork phase looks largely done – now the market will want proof that the business can actually earn its keep.

OptiBiotix AGM date and shareholder details

OptiBiotix’s AGM will be held at 2pm on 23 June 2026 at the offices of Marex, 155 Bishopsgate, London, EC2M 3TQ. Shareholders wishing to attend in person are asked to notify the company by 19 June due to building security requirements.

For existing holders, the AGM may be worth watching closely. This is one of those moments where investors should be asking management not just about pipeline and partnerships, but about timing, margins, cash discipline and what success by the end of 2026 actually looks like in hard numbers.